—
The global cancer diagnostics market size reached USD 140.20 Billion in 2022 and is expected to register a revenue CAGR of 8.3% during the forecast period, according to the latest analysis by Emergen Research. For many years, there has been a persistent health issue with cancer, the world's top cause of death. However, improvements in cancer diagnostics have completely changed how the disease is found, identified, and treated. Recent years have seen a considerable increase in the market for cancer diagnostics, which has been fueled by factors like rising cancer prevalence, technical breakthroughs, and rising public awareness of the importance of early cancer detection. To further advance cancer diagnostics and successfully combat cancer, there are obstacles and hurdles that must be overcome.
The rising incidence of cancer worldwide is one of the main factors driving the market for cancer diagnostics. To address this growing burden, governments, and healthcare organizations all over the world are giving priority to cancer screening and early detection programs. For instance, to encourage cancer screening and increase awareness of the value of early diagnosis, the National Cancer Institute in the United States has put in place a number of projects.
The market for cancer diagnostics has expanded significantly as a result of technological improvements. The accuracy and sensitivity of cancer diagnosis have increased with the development of advanced imaging techniques including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Additionally, the development of liquid biopsy, a non-invasive technique for identifying genetic abnormalities associated with cancer in blood samples, has revolutionized cancer diagnostics by making it possible to detect and monitor cancer early on with the least amount of invasiveness.
Request a Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @https://www.emergenresearch.com/request-sample/1729
The industry for cancer diagnostics still faces a number of obstacles despite the advancements. The high cost of cancer diagnostics is one of the major difficulties. Certain populations, particularly in low-income nations, may not have access to cancer diagnoses because of the high cost of advanced imaging techniques and genetic testing. Additionally, given the complexity of cancer diagnoses, not all healthcare environments have access to skilled medical personnel and specialized infrastructure. This can make it difficult to diagnose cancer in a fast and reliable manner, especially in locations with limited resources.
The market for cancer diagnostics is also impacted by regulatory issues. The introduction of cutting-edge diagnostic solutions to the market is hampered by the lengthy and expensive approval process for cancer diagnostic tests and technologies. Additionally, a lack of standardization and harmonization in cancer diagnostics may cause test findings to vary, which could affect the precision and dependability of cancer diagnosis. The market can expand by addressing these regulatory issues and implementing standardized cancer detection procedures.
Cancer Diagnostics Market Segmentation:
The outlook for cancer types in terms of revenue in USD billion from 2019 to 2032 is as follows: Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, and Others. Among these, Breast Cancer is projected to generate significant revenue during the forecast period, followed by Lung Cancer and Colorectal Cancer. Cervical Cancer and Prostate Cancer are also expected to contribute to the overall revenue in the cancer diagnostics and treatment market. The revenue generated from Other types of cancer is also expected to contribute to the market growth.
In terms of product types, Consumables and Instruments are expected to generate revenue in the cancer diagnostics and treatment market from 2019 to 2032. Consumables, such as reagents and assays, are projected to generate significant revenue due to their continuous usage in cancer diagnostics and treatment procedures. Instruments, such as diagnostic equipment and surgical instruments, are also expected to contribute to the market revenue during the forecast period.
In terms of technology types, IVD (In Vitro Diagnostics) testing and Imaging Technology are expected to generate revenue in the cancer diagnostics and treatment market from 2019 to 2032. IVD testing, which includes various laboratory-based tests for cancer detection, is expected to generate significant revenue due to its widespread adoption in cancer diagnostics. Imaging Technology, such as CT scans, MRI, and PET scans, are also projected to contribute to the market revenue as they play a crucial role in cancer diagnosis and monitoring.
In terms of end-use, Hospitals and Specialty Cancer Centers & Clinics are expected to generate revenue in the cancer diagnostics and treatment market from 2019 to 2032. Hospitals, being the primary healthcare setting for cancer diagnostics and treatment, are projected to generate significant revenue. Specialty Cancer Centers & Clinics, which provide specialized care and treatment for cancer patients, are also expected to contribute to the market revenue. Other healthcare settings, such as diagnostic laboratories and research institutes, are also projected to generate revenue in the cancer diagnostics and treatment market during the forecast period.
The report also provides a regional analysis of the market, with a focus on North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @https://www.emergenresearch.com/industry-report/cancer-diagnostics-market
Some Key Highlights From the Report
- The instruments segment accounted for the largest revenue share in 2022 due to its high usage in cancer diagnostics and treatment procedures. Instruments such as diagnostic equipment, surgical instruments, and other specialized tools play a crucial role in various aspects of cancer management, including diagnosis, staging, monitoring, and treatment. These instruments are utilized in procedures such as biopsies, surgeries, radiation therapy, and chemotherapy, among others.
- The lung cancer segment is expected to register a steady CAGR during the forecast period due to various factors. Lung cancer is one of the most common types of cancer worldwide, and its incidence has been increasing in recent years. The growing prevalence of risk factors such as smoking, air pollution, and occupational exposure to carcinogens has contributed to the rising incidence of lung cancer, driving the demand for lung cancer diagnostics and treatment.
- Europe accounted for a significantly large revenue share in 2022 due to the increasing prevalence of lung cancer in the region. Europe has a relatively high incidence of lung cancer, with several risk factors such as smoking, environmental pollution, and occupational exposures contributing to the disease burden. This has led to a significant demand for lung cancer diagnostics and treatment in the region, driving the revenue growth in 2022.
- Some major companies in the global market report include, F. Hoffman-La Roche Ltd., QIAGEN., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Merck KGaA, Siemens, Danaher Corporation, Koninklijke Philips N.V.
- A pioneer in the development and promotion of precision oncology solutions based on next-generation sequencing (NGS), Resolution Bioscience Inc., was acquired by Agilent Technologies Inc. on March 2, 2021, according to a legally binding agreement. The acquisition adds to and broadens Agilent's capabilities in NGS-based cancer diagnostics and provides the business with access to cutting-edge equipment to better serve the demands of the quickly developing precision medicine market. According to the terms of the agreement, Agilent will have to pay USD 550 million in cash at closure and up to an extra USD 145 million if future performance goals are met.
Explore All of our Published Healthcare and Pharmaceuticals Titles@ https://www.emergenresearch.com/industry-details/healthcare-and-pharmaceuticals
About Us: Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend's existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Info:
Name: Eric Lee
Email: Send Email
Organization: Emergen Research
Address: 14671 110 Avenue, Surrey, British Columbia, V3R2A9
Phone: 604757975
Website: https://www.emergenresearch.com/
Release ID: 89094708
Google
RSS